Evidence mapPaperPMID 24577151Full record

ArticleClinical pharmacology and therapeutics2014

Integrating systems biology sources illuminates drug action.

A Gottlieb, R B Altman

Abstract read
In one paragraph

Article in Clinical pharmacology and therapeutics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
6.3field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 21 citations in OpenAlex.

  1. Validation approaches for computational drug repurposing: a review.AMIA ... Annual Symposium proceedings. AMIA Symposium · 2023
    Review
  2. Article
  3. Article
  4. Article
  5. DIFFERENTIAL PATHWAY DEPENDENCY DISCOVERY ASSOCIATED WITH DRUG RESPONSE ACROSS CANCER CELL LINES.Pacific Symposium on Biocomputing. Pacific Symposium on Biocomputing · 2017
    Article
  6. Article
  7. Article
  8. Article
  9. Ranking adverse drug reactions with crowdsourcing.Journal of medical Internet research · 2015
    Article
  10. Systems pharmacology augments drug safety surveillance.Clinical pharmacology and therapeutics · 2015
    Article
  11. Article
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

A GottliebDepartment of Genetics, Stanford University, Stanford, California, USA.
R B Altman1] Department of Genetics, Stanford University, Stanford, California, USA [2] Department of Bioengineering, Stanford University, Stanford, California, USA.
Stanford University · US

Funding

THE STANFORD PHARMACOGENETICS KNOWLEDGE BASEU01GM061374 · STANFORD UNIVERSITY · 2000 to 2005
$13.2M
MODELING AND COMPUTING WITH UNCERTAIN STRUCTURESR01LM005652 · STANFORD UNIVERSITY · 2000 to 2005
$1.7M
MODELING AND COMPUTING WITH UNCERTAIN STRUCTURESR29LM005652 · STANFORD UNIVERSITY · 1994 to 1998
NIGMS NIH HHS GM102365NIGMS NIH HHS GM61374NIGMS NIH HHS R01 GM102365NIGMS NIH HHS R24 GM061374NIGMS NIH HHS U01 GM061374NIMH NIH HHS P50 MH094267NLM NIH HHS LM05652NLM NIH HHS R01 LM005652
6 · The paper itself

Abstract

There are significant gaps in our understanding of the pathways by which drugs act. This incomplete knowledge limits our ability to use mechanistic molecular information rationally to repurpose drugs, understand their side effects, and predict their interactions with other drugs. Here, we present DrugRouter, a novel method for generating drug-specific pathways of action by linking target genes, disease genes, and pharmacogenes using gene interaction networks. We construct pathways for more than a hundred drugs and show that the genes included in our pathways (i) co-occur with the query drug in the literature, (ii) significantly overlap or are adjacent to known drug-response pathways, and (iii) are adjacent to genes that are hits in genome-wide association studies assessing drug response. Finally, these computed pathways suggest novel drug-repositioning opportunities (e.g., statins for follicular thyroid cancer), gene-side effect associations, and gene-drug interactions. Thus, DrugRouter generates hypotheses about drug actions using systems biology data.

Indexed as

AlgorithmsDatabases, FactualDrug InteractionsDrug RepositioningGene Regulatory NetworksHumansPharmacogeneticsPharmacologySignal TransductionSystems Biology

Identifiers

PMID24577151
PMCPMC4029855
OpenAlexW2037927825

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.